IJCM  Vol.6 No.10 , October 2015
A Comparison of Cytokine Profiles of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis Patients
Background: Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (CFS/ME), is a debilitating condition that presents with a range of symptoms, including fatigue, cognitive dysfunction, muscular and joint pain, and may be immune-mediated. In particular, patients exhibit abnormal cytokine expression. Similarly, in Multiple Sclerosis (MS), patients display neuroimmunological symptoms, and abnormal cytokine expression, with some overlap in symptomology with CFS/ME. The purpose of this study was to compare Th1, Th2, Th17 cytokines, inflammatory cytokines and chemokines, in healthy controls, CFS/ME and MS patients. Methods: Serum samples were collected from healthy controls (n = 16, mean age = 50 ± 11.85 years), CFS/ME patients (n = 16, mean age = 49.88 ± 9.54 years) and MS patients (n = 11, mean age = 52.75 ± 12.81 years). The concentrations of 27 cytokines (IFN-γ, TNF-α, IL-12, IL-2, IL-1β, IL-4, IL-6, IL-10, IL-13, IL-5, IL-17, IL-1ra, IL-7, IL-8, IL-9, eotaxin, IP-10, MCP-1, MIP1α, MIP1β, PDGF-bb, RANTES, basic FGF, GCSF, GMCSF, VEGF and IL-15) were measured using a Bio-Plex Pro™ kit. Results: IFN-γ, IL-10 and IL-5 were significantly higher in the serum of both CFS/ME and MS patients compared to the healthy controls (p ≤ 0.041). However, only the MS patients had significantly elevated levels of IL-12, IL-1β, IL-4, IL-13, IL-6, IL-17, IL-1ra, IL-7, IL-9, eotaxin, IL-10, MIP1α, basic FGF, GCSF and VEGF compared to the CFS/ME patients and controls (p ≤ 0.04). There were no significant differences between groups for IL-8, MCP-1, MIP1β, RANTES, GMCSF, TNF-α, and IL-2. Conclusion: CFS/ME and MS patients both displayed abnormal cytokine levels, with dual expression of Th1 and Th2 cytokines. Further research into cytokines such as IFN-γ, IL-10 and IL-5, with the use of a specific CFS/ME case definition and sensitive cytokine assays, is required to improve the understanding of the pathophysiology of CFS/ME.

Cite this paper
Wong, N. , Nguyen, T. , Brenu, E. , Broadley, S. , Staines, D. and Marshall-Gradisnik, S. (2015) A Comparison of Cytokine Profiles of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis Patients. International Journal of Clinical Medicine, 6, 769-783. doi: 10.4236/ijcm.2015.610103.
[1]   Carruthers, B.M., et al. (2011) Myalgic Encephalomyelitis: International Consensus Criteria. Journal of Internal Medicine, 270, 326-338.

[2]   Hiscott, J. and Ware, C. (2011) Cytokines. Current Opinion in Immunology, 23, 561-563.

[3]   Lloyd, A., et al. (1992) Cell-Mediated Immunity in Patients with Chronic Fatigue Syndrome, Healthy Control Subjects and Patients with Major Depression. Clinical & Experimental Immunology, 87, 76-79.

[4]   Peakman, M., et al. (1997) Clinical Improvement in Chronic Fatigue Syndrome Is Not Associated with Lymphocyte Subsets of Function or Activation. Clinical Immunology and Immunopathology, 82, 83-91.

[5]   Rasmussen, A., et al. (1994) Chronic Fatigue Syndrome—A Controlled Cross-Sectional Study. Ugeskrift for Laeger, 156, 6836-6840.

[6]   Fletcher, M.A., et al. (2009) Plasma Cytokines in Women with Chronic Fatigue Syndrome. Journal of Translational Medicine, 7, 96.

[7]   Chao, C.C., et al. (1991) Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome. Cytokine, 3, 292-298.

[8]   Brenu, E., et al. (2012) Longitudinal Investigation of Natural Killer Cells and Cytokines in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Journal of Translational Medicine, 10, 88.

[9]   Brenu, E., et al. (2011) Immunological Abnormalities as Potential Biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Journal of Translational Medicine, 9, 81.

[10]   Broderick, G., et al. (2010) A Formal Analysis of Cytokine Networks in Chronic Fatigue Syndrome. Brain, Behavior, and Immunity, 24, 1209-1217.

[11]   Patarca, R., Klimas, N.G., Lugtendorf, S., et al. (1994) Dysregulated Expression of Tumor Necrosis Factor in Chronic Fatigue Syndrome: Interrelations with Cellular Sources and Patterns of Soluble Immune Mediator Expression. Clinical Infectious Diseases, 18, S147-S153.

[12]   Cheney, P.R., Dorman, S.E. and Bell, D.S. (1989) Interleukin-2 and the Chronic Fatigue Syndrome. Annals of Internal Medicine, 110, 321-321.

[13]   Ashwani, A. (2010) Multiple Sclerosis: A Review. International Journal of Pharmaceutical Sciences and Research, 1, 13.

[14]   Compstom, A. and Coles, A. (2008) Multiple Sclerosis. The Lancet, 372, 1507-1517.

[15]   Hauser, S.L. and Oksenberg, J.R. (2006) The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration. Neuron, 52, 61-76.

[16]   Lublin, F.D. and Reingold, S.C. (1996) Defining the Clinical Course of Multiple Sclerosis Results of an International Survey. Neurology, 46, 907-911.

[17]   Panitch, H., Hirsch, R.L., Haley, A.S., et al. (1987) Exacerbations of Multiple Sclerosis in Patients Treated with Gamma Interferon. The Lancet, 329, 893-895.

[18]   Beck, J., Rondot, P., Catinot, L., et al. (1988) Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger off Exacerbations? Acta Neurologica Scandinavica, 78, 318-323.

[19]   Selmaj, K., Raine, C.S., Cannella, B. and Brosnan, C.F. (1991) Identification of Lymphotoxin and Tumor Necrosis Factor in Multiple Sclerosis Lesions. Journal of Clinical Investigation, 87, 949.

[20]   Zipp, F., Weber, F., Huber, S., et al. (1995) Genetic Control of Multiple Sclerosis: Increased Production of Lymphotoxin and Tumor Necrosis Factor-α by HLA-DR2+ T Cells. Annals of Neurology, 38, 723-730.

[21]   Imitola, J., Chitnis, T. and Khoury, S.J. (2005) Cytokines in Multiple Sclerosis: From Bench to Bedside. Pharmacology & Therapeutics, 106, 163-177.

[22]   Cannella, B. and Raine, C.S. (1995) The Adhesion Molecule and Cytokine Profile of Multiple Sclerosis Lesions. Annals of Neurology, 37, 424-435.

[23]   Smith, D.R., Balashov, K.E., Hafler, D.A., et al. (1997) Immune Deviation Following Pulse Cyclophosphamide/Methylprednisolone Treatment of Multiple Sclerosis: Increased Interleukin-4 Production and Associated Eosinophilia. Annals of Neurology, 42, 313-318.

[24]   Stelmasiak, Z., Koziol-Montewka, M., Dobosz, B., et al. (2000) Interleukin-6 Concentration in Serum and Cerebrospinal Fluid in Multiple Sclerosis Patients. Medical Science Monitor, 6, 1104-1108.

[25]   Chen, Y.-C., Yang, X., Miao, L., et al. (2012) Serum Level of Interleukin-6 in Chinese Patients with Multiple Sclerosis. Journal of Neuroimmunology, 249, 109-111.

[26]   Rieckmann, P., Albrecht, M., Kitze, B., et al. (1994) Cytokine mRNA Levels in Mononuclear Blood Cells from Patients with Multiple Sclerosis. Neurology, 44, 1523-1523.

[27]   Correale, J., Gilmore, W., McMillan, M., et al. (1995) Patterns of Cytokine Secretion by Autoreactive Proteolipid Protein-Specific T Cell Clones during the Course of Multiple Sclerosis. The Journal of Immunology, 154, 2959-2968.

[28]   Correale, J., McMillan, M., McCarthy, K., Le, T., Weiner, L.P., et al. (1995) Isolation and Characterization of Autoreactive Moteolioid Protein-Peptide Specific T-Cell Clones from Multiple Sclerosis Patients. Neurology, 45, 1370-1375.

[29]   Pelfrey, C.M., Rudick, R.A., Cotleur, A.C., et al. (2000) Quantification of Self-Recognition in Multiple Sclerosis by Single-Cell Analysis of Cytokine Production. The Journal of Immunology, 165, 1641-1651.

[30]   Polman, C.H., Reingold, S.C., Banwell, B., et al. (2011) Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of Neurology, 69, 292-302.

[31]   Laurikkala, J., et al. (2000) Informal Identification of Outliers in Medical Data. Proceedings of the Fifth International Workshop on Intelligent Data Analysis in Medicine and Pharmacology, Berlin, 22 August 2000.

[32]   Patarca, R. (2001) Cytokines and Chronic Fatigue Syndrome. Annals of the New York Academy of Sciences, 933, 185-200.

[33]   Young, H.A. and Hardy, K.J. (1995) Role of Interferon-Gamma in Immune Cell Regulation. Journal of Leukocyte Biology, 58, 373-381.

[34]   Bradley, L., Dalton, D. and Croft, M. (1996) A Direct Role for IFN-Gamma in Regulation of Th1 Cell Development. Journal of Immunology, 157, 1350-1358.

[35]   Kibler, R., Lucas, D.O., Hicks, M.J., et al. (1985) Immune Function in Chronic Active Epstein-Barr Virus Infection. Journal of Clinical Immunology, 5, 46-54.

[36]   Brenu, E., Staines, D.R., Baskurt, O.K., et al. (2010) Immune and Hemorheological Changes in Chronic Fatigue Syndrome. Journal of Translational Medicine, 8, 1.

[37]   Klimas, N.G., Morgan, R., Fletcher, M.A., et al. (1990) Immunologic Abnormalities in Chronic Fatigue Syndrome. Journal of Clinical Microbiology, 28, 1403-1410.

[38]   Levine, P.H., Whiteside, T.L., Friberg, D., et al. (1998) Dysfunction of Natural Killer Activity in a Family with Chronic Fatigue Syndrome. Clinical Immunology and Immunopathology, 88, 96-104.

[39]   Issazadeh, S., Ljungdahl, A., Höjeberg, B., et al. (1995) Cytokine Production in the Central Nervous System of Lewis Rats with Experimental Autoimmune Encephalomyelitis: Dynamics of mRNA Expression for Interleukin-10, Interleukin-12, Cytolysin, Tumor Necrosis Factor α and Tumor Necrosis Factor β. Journal of Neuroimmunology, 61, 205-212.

[40]   Pokryszko-Dragan, A., Frydecka, I., Kosmaczewska, A., et al. (2012) Stimulated Peripheral Production of Interferon-Gamma Is Related to Fatigue and Depression in Multiple Sclerosis. Clinical Neurology and Neurosurgery, 114, 1153-1158.

[41]   Seppia, D., Puthenparampil, M., Federle, L., et al. (2014) Cerebrospinal Fluid IL-1β Correlates with Cortical Pathology Load in Multiple Sclerosis at Clinical Onset. Journal of Neuroimmunology, 270, 56-60.

[42]   Takahashi, J.L., Giuliani, F., Power, C., et al. (2003) Interleukin-1β Promotes Oligodendrocyte Death through Glutamate Excitotoxicity. Annals of Neurology, 53, 588-595.

[43]   Vignali, D.A.A. and Kuchroo, V.K. (2012) IL-12 Family Cytokines: Immunological Playmakers. Nature Immunology, 13, 722-728. http://dx.doi.org/10.1038/ni.2366

[44]   Windhagen, A., Newcombe, J., Dangond, F., et al. (1995) Expression of Costimulatory Molecules B7-1 (CD80), B7-2 (CD86), and Interleukin 12 Cytokine in Multiple Sclerosis Lesions. The Journal of Experimental Medicine, 182, 1985-1996.

[45]   Mocellin, S., Panelli, M.C., Wang, E., et al. (2003) The Dual Role of IL-10. Trends in Immunology, 24, 36-43.

[46]   Hohnoki, K., Inoue, A. and Koh, C.-S. (1998) Elevated Serum Levels of IFN-γ, IL-4 and TNF-α Unelevated Serum Levels of IL-10 in Patients with Demyelinating Diseases during the Acute Stage. Journal of Neuroimmunology, 87, 27-32.

[47]   Scheffold, A., Murphy, K.M. and Höfer, T. (2007) Competition for Cytokines: Treg Cells Take All. Nature Immunology, 8, 1285-1287.

[48]   Brenu, E., Huth, T.K., Hardcastle, S.L., et al. (2014) Role of Adaptive and Innate Immune Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. International Immunology, 26, 233.

[49]   Curriu, M., Carrillo, J., Massanella, M., et al. (2013) Screening NK-, B- and T-Cell Phenotype and Function in Patients Suffering from Chronic Fatigue Syndrome. Journal of Translational Medicine, 11, 68.

[50]   Couper, K.N., Blount, D.G. and Riley, E.M. (2008) IL-10: The Master Regulator of Immunity to Infection. The Journal of Immunology, 180, 5771-5777.

[51]   Natelson, B.H., Weaver, S.A., Tseng, C.L., et al. (2005) Spinal Fluid Abnormalities in Patients with Chronic Fatigue Syndrome. Clinical and Diagnostic Laboratory Immunology, 12, 52-55.

[52]   Venken, K., Hellings, N., Thewissen, M., et al. (2008) Compromised CD4+ CD25high Regulatory T-Cell Function in Patients with Relapsing-Remitting Multiple Sclerosis Is Correlated with a Reduced Frequency of FOXP3-Positive Cells and Reduced FOXP3 Expression at the Single-Cell Level. Immunology, 123, 79-89.

[53]   Venken, K., Hellings, N., Hensen, K., et al. (2006) Secondary Progressive in Contrast to Relapsing-Remitting Multiple Sclerosis Patients Show a Normal CD4+ CD25+ Regulatory T-Cell Function and FOXP3 Expression. Journal of Neuroscience Research, 83, 1432-1446.

[54]   Venken, K., Hellings, N., Broekmans, T., et al. (2008) Natural Naive CD4+ CD25+ CD127low Regulatory T Cell (Treg) Development and Function Are Disturbed in Multiple Sclerosis Patients: Recovery of Memory Treg Homeostasis during Disease Progression. The Journal of Immunology, 180, 6411-6420.

[55]   Soldan, S.S., Alvarez Retuerto, A.I., Sicotte, N.L., et al. (2004) Dysregulation of IL-10 and IL-12p40 in Secondary Progressive Multiple Sclerosis. Journal of Neuroimmunology, 146, 209-215.

[56]   Michel, L., Degauque, N., Garcia, A., et al. (2011) Loss of IL-10 Secretion by Regulatory B Lymphocytes in Multiple Sclerosis Patients. Journal of Translational Medicine, 9, 25-25.

[57]   Huang, W.-X., Huang, P., Link, H. and Hillert, J. (1999) Cytokine Analysis in Multiple Sclerosis by Competitive RT-PCR: A Decreased Expression of IL-10 and an Increased Expression of TNF-α in Chronic Progression. Multiple Sclerosis, 5, 342-348.

[58]   Tuohy, V.K., Yu, M., Yin, L., et al. (2000) Modulation of the IL-10/IL-12 Cytokine Circuit by Interferon-Beta Inhibits the Development of Epitope Spreading and Disease Progression in Murine Autoimmune Encephalomyelitis. Journal of Neuroimmunology, 111, 55.

[59]   Takatsu, K. (2011) Interleukin-5 and IL-5 Receptor in Health and Diseases. Proceedings of the Japan Academy Series B, Physical and Biological Sciences, 87, 463-485.

[60]   Fluge, Ø., Bruland, O., Risa, K., et al. (2011) Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. PLoS ONE, 6, e26358.

[61]   Bradley, A., Ford, B. and Bansal, A. (2013) Altered Functional B Cell Subset Populations in Patients with Chronic Fatigue Syndrome Compared to Healthy Controls. Clinical and Experimental Immunology, 172, 73-80.

[62]   Franciotta, D., Salvetti, M., Lolli, F., et al. (2008) B Cells and Multiple Sclerosis. Lancet Neurology, 7, 852-858.

[63]   Hauser, S.L., Waubant, E., Arnold, D.L., et al. (2008) B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. The New England Journal of Medicine, 358, 676-688.

[64]   Corren, J. (2012) Inhibition of Interleukin-5 for the Treatment of Eosinophilic Diseases. Discovery Medicine, 13, 305-312.

[65]   Conti, F., Priori, R., Valesini, G., et al. (1996) Eosinophil Cationic Protein Serum Levels and Allergy in Chronic Fatigue Syndrome. Allergy, 51, 124-127.

[66]   Lassmann, H. and Ransohoff, R.M. (2004) The CD4-Th1 Model for Multiple Sclerosis: A Crucial Re-Appraisal. Trends in Immunology, 25, 132-137.

[67]   Oleksowicz, L. and Dutcher, J.P. (1994) A Review of the New Cytokines: IL-4, IL-6, IL-11, and IL-12. American Journal of Therapeutics, 1, 107-115.

[68]   Hohnoki, K., Inoue, A. and Koh, C.-S. (1998) Elevated Serum Levels of IFN-γ, IL-4 and TNF-α Unelevated Serum Levels of IL-10 in Patients with Demyelinating Diseases during the Acute Stage. Journal of Neuroimmunology, 87, 27-32.

[69]   Link, J., Söderström, M., Olsson, T., et al. (1994) Increased Transforming Growth Factor-β, Interleukin-4, and Interferon-γ in Multiple Sclerosis. Annals of Neurology, 36, 379-386.

[70]   Bartosik-Psujek, H. and Stelmasiak, Z. (2005) Correlations between IL-4, IL-12 Levels and CCL2, CCL5 Levels in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Journal of Neural Transmission, 112, 797-803.

[71]   Skowera, A., Cleare, A., Blair, D., et al. (2004) High Levels of Type 2 Cytokine-Producing Cells in Chronic Fatigue Syndrome. Clinical & Experimental Immunology, 135, 294-302.

[72]   Wynn, T.A. (2003) IL-13 Effector Functions. Annual Review of Immunology, 21, 425-456.

[73]   Martins, T.B., Rose, J.W., Jaskowski, T.D., et al. (2011) Analysis of Proinflammatory and Anti-Inflammatory Cytokine Serum Concentrations in Patients with Multiple Sclerosis by Using a Multiplexed Immunoassay. American Journal of Clinical Pathology, 136, 696-704.

[74]   Musabak, U., Demirkaya, S., Genç, G., et al. (2011) Serum Adiponectin, TNF-α, IL-12p70, and IL-13 Levels in Multiple Sclerosis and the Effects of Different Therapy Regimens. Neuroimmunomodulation, 18, 57-66.

[75]   Rossi, S., Mancino, R., Bergami, A., et al. (2011) Potential Role of IL-13 in Neuroprotection and Cortical Excitability Regulation in Multiple Sclerosis. Multiple Sclerosis, 17, 1301-1312.

[76]   Korn, T., Bettelli, E., Oukka, M., et al. (2009) IL-17 and Th17 Cells. Annual Review of Immunology, 27, 485-517.

[77]   Gaffen, S.L. (2008) An Overview of IL-17 Function and Signaling. Cytokine, 43, 402-407.

[78]   Al Omar, S., Flanagan, B.F., Almehmadi, M. and Christmas, S.E. (2013) The Effects of IL-17 upon Human Natural Killer Cells. Cytokine, 62, 123-130.

[79]   Chen, Y.-C., Chen, S.D., Miao, L., et al. (2012) Serum Levels of Interleukin (IL)-18, IL-23 and IL-17 in Chinese Patients with Multiple Sclerosis. Journal of Neuroimmunology, 243, 56-60.

[80]   Kawanokuchi, J., Shimizu, K., Nitta, A., et al. (2008) Production and Functions of IL-17 in Microglia. Journal of Neuroimmunology, 194, 54-61.

[81]   Ishihara, K. and Hirano, T. (2002) IL-6 in Autoimmune Disease and Chronic Inflammatory Proliferative Disease. Cytokine & Growth Factor Reviews, 13, 357-368.

[82]   Linde, A., Andersson, B., Svenson, S.B., et al. (1992) Serum Levels of Lymphokines and Soluble Cellular Receptors in Primary Epstein-Barr Virus Infection and in Patients with Chronic Fatigue Syndrome. Journal of Infectious Diseases, 165, 994-1000.

[83]   Laine, M.L., Farré, M.A., Crusius, J.B.A., et al. (2000) The Mouthwash: A Non-Invasive Sampling Method to Study Cytokine Gene Polymorphisms. Journal of Periodontology, 71, 1315-1318.

[84]   Nicoletti, F., Patti, F., DiMarco, R., et al. (1996) Circulating Serum Levels of IL-1ra in Patients with Relapsing Remitting Multiple Sclerosis Are Normal during Remission Phases but Significantly Increased Either during Exacerbations or in Response to IFN-β Treatment. Cytokine, 8, 395-400.

[85]   Graber, J.J. and Dhib-Jalbut, S. (2014) Biomarkers of Interferon Beta Therapy in Multiple Sclerosis. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research, 34, 600-604.

[86]   Goswami, R. and Kaplan, M.H. (2011) A Brief History of IL-9. Journal of Immunology, 186, 3283-3288.

[87]   Nowak, E.C., Weaver, C.T., Turner, H., et al. (2009) IL-9 as a Mediator of Th17-Driven Inflammatory Disease. The Journal of Experimental Medicine, 206, 1653-1660.

[88]   Franciotta, D., Zardini, E., Ravaglia, S., et al. (2006) Cytokines and Chemokines in Cerebrospinal Fluid and Serum of Adult Patients with Acute Disseminated Encephalomyelitis. Journal of the Neurological Sciences, 247, 202-207.

[89]   Narikawa, K., Misu, T., Fujihara, K., et al. (2004) CSF Chemokine Levels in Relapsing Neuromyelitisoptica and Multiple Sclerosis. Journal of Neuroimmunology, 149, 182-186.

[90]   Öckinger, J., Stridh, P., Beyeen, A.D., et al. (2009) Genetic Variants of CC Chemokine Genes in Experimental Autoimmune Encephalomyelitis, Multiple Sclerosis and Rheumatoid Arthritis. Genes and Immunity, 11, 142-154.

[91]   Liu, M., Guo, S., Hibbert, J.M., et al. (2011) CXCL10/IP-10 in Infectious Diseases Pathogenesis and Potential Therapeutic Implications. Cytokine and Growth Factor Reviews, 22, 121-130.

[92]   Trebst, C. and Ransohoff, R.M. (2001) Investigating Chemokines and Chemokine Receptors in Patients with Multiple Sclerosis: Opportunities and Challenges. Archives of Neurology, 58, 1975-1980.

[93]   Scarpini, E., Galimberti, D., Baron, P., et al. (2002) IP-10 and MCP-1 Levels in CSF and Serum from Multiple Sclerosis Patients with Different Clinical Subtypes of the Disease. Journal of the Neurological Sciences, 195, 41-46.

[94]   Maurer, M. and Von Stebut, E. (2004) Macrophage Inflammatory Protein-1. The International Journal of Biochemistry & Cell Biology, 36, 1882-1886.

[95]   Simpson, J.E., Newcombe, J., Cuzner, M.L. and Woodroofe, M.N. (1998) Expression of Monocyte Chemoattractant Protein-1 and Other Beta-Chemokines by Resident Glia and Inflammatory Cells in Multiple Sclerosis Lesions. Journal of Neuroimmunology, 84, 238-249.

[96]   Goddard, D.R., Berry, M., Kirvell, S.L., et al. (2001) Fibroblast Growth Factor-2 Inhibits Myelin Production by Oligodendrocytes in Vivo. Molecular and Cellular Neuroscience, 18, 557-569.

[97]   Clemente, D., Ortega, M.C., Arenzana, F.J., et al. (2011) FGF-2 and Anosmin-1 Are Selectively Expressed in Different Types of Multiple Sclerosis Lesions. The Journal of Neuroscience, 31, 14899-14909.

[98]   Rottlaender, A., Villwock, H., Addicks, K. and Kuerten, S. (2011) Neuroprotective Role of Fibroblast Growth Factor-2 in Experimental Autoimmune Encephalomyelitis. Immunology, 133, 370-378.

[99]   Hamilton, J.A. (2008) Colony-Stimulating Factors in Inflammation and Autoimmunity. Nature Reviews. Immunology, 8, 533-544.

[100]   Debruyne, J., Philippe, J., Dereuck, J., et al. (1998) Relapse Markers in Multiple Sclerosis: Are in Vitro Cytokine Production Changes Reflected by Circulatory T-Cell Phenotype Alterations? Multiple Sclerosis, 4, 193-197.

[101]   Naegele, M., Tillack, K., Reinhardt, S., et al. (2012) Neutrophils in Multiple Sclerosis Are Characterized by a Primed Phenotype. Journal of Neuroimmunology, 242, 60-71.

[102]   Morris, G. and Maes, M. (2013) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Encephalomyelitis Disseminata/Multiple Sclerosis Show Remarkable Levels of Similarity in Phenomenology and Neuroimmune Characteristics. BMC Medicine, 11, 205. http://dx.doi.org/10.1186/1741-7015-11-205

[103]   Visser, J., Blauw, B., Hinloopen, B., et al. (1998) CD4 T Lymphocytes from Patients with Chronic Fatigue Syndrome Have Decreased Interferon-Gamma Production and Increased Sensitivity to Dexamethasone. The Journal of Infectious Diseases, 177, 451-454.

[104]   Fukuda, K., Straus, S.E., Hickie, I., et al. (1994) The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study. Annals of Internal Medicine, 121, 953-959.